Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
Phase I trial results (NCT05097911) have demonstrated that MTL-CEBPA has a good safety profile for the treatment of hepatocellular carcinoma and may enhance the therapeutic effects of tyrosine kinase inhibitors by modulating immune suppression
46c, 875881
kumar Dinda, M
This can occur through intracellular enzymatic antioxidant mechanisms or through the action of antioxidants
KLOW provides researchers with an opportunity to investigate how multiple peptide signaling pathways interact to regulate cellular communication, inflammatory physiology, tissue adaptation, and the biological mechanisms responsible for maintaining structural integrity under changing physiological conditions
US$ 21.08
US$ 26.13
US$ 29.28
US$ 26.95
